Edition:
United States

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

55.27USD
24 Mar 2017
Change (% chg)

$1.14 (+2.11%)
Prev Close
$54.13
Open
$54.30
Day's High
$55.57
Day's Low
$54.18
Volume
117,666
Avg. Vol
235,667
52-wk High
$67.65
52-wk Low
$34.45

AGIO.OQ

Chart for AGIO.OQ

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 1.96
Market Cap(Mil.): $2,334.29
Shares Outstanding(Mil.): 42.23
Dividend: --
Yield (%): --

Financials

  AGIO.OQ Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -5.06 -- --
ROI: -44.21 -2.56 13.01
ROE: -56.41 5.14 14.16

BRIEF-Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene

* Agios announces MTAP pathway research program as development program and development candidate under master research and collaboration agreement with Celgene

Mar 13 2017

BRIEF-Agios says cash, marketable securities were $573.6 mln as of Dec. 31

* Agios reports fourth quarter and full year 2016 financial results and highlights key 2017 milestones

Feb 16 2017

BRIEF-Agios pharmaceuticals AG-120 NDA submission for IDH1M R/R AML planned by year end 2017

* AG-120 NDA submission for IDH1M R/R AML planned by year end 2017

Jan 09 2017

BRIEF-Agios provides early-stage data on AG-120 in glioma, chondrosarcoma patients

* Agios announces phase 1 data from dose expansion cohorts of AG-120 in patients with IDH1 mutant positive glioma and chondrosarcoma Source text for Eikon: Further company coverage:

Nov 18 2016

BRIEF-Agios posts Q3 shr loss $1.63

* Agios Pharmaceuticals inc - now expects to end 2016 with more than $550 million of cash, cash equivalents and marketable securities

Nov 03 2016

More From Around the Web

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $34.00 -0.29
Novartis AG (NOVN.S) CHF73.75 -0.40
Roche Holding Ltd. (ROG.S) CHF252.90 +0.30
Roche Holding Ltd. (RO.S) CHF252.50 0.00
Sanofi SA (SASY.PA) €82.87 -0.43
AstraZeneca plc (AZN.L) 4,928.50 -31.00
GlaxoSmithKline plc (GSK.L) 1,670.50 -4.50
Eli Lilly and Co (LLY.N) $84.18 -0.24
Shire PLC (SHP.L) 4,676.50 +11.50
Shire PLC (3159084.L) -- --

Earnings vs. Estimates